Format

Send to

Choose Destination
J Neuroimmunol. 2016 Jan 15;290:103-8. doi: 10.1016/j.jneuroim.2015.11.025. Epub 2015 Nov 28.

The limited capacity of malignant glioma-derived exosomes to suppress peripheral immune effectors.

Author information

1
Department of Neurological Surgery, UCSF, San Francisco, CA, USA; Clinical and Translational Science Institute, UCSF, San Francisco, CA, USA.
2
Department of Neurological Surgery, UCSF, San Francisco, CA, USA. Electronic address: Michael.ivan@jhsmiami.org.
3
Department of Neurological Surgery, UCSF, San Francisco, CA, USA.

Abstract

Tumor-derived microvesicular exosomes permit intercellular communication both locally and systemically by delivering a snapshot of the tumor cell's constituents. We thus investigated whether exosomes mediate malignant glioma's facility for inducing peripheral immunosuppression. In Western blot and RT-PCR analyses, glioma-derived exosomes displayed exosome-specific markers, but failed to recapitulate the antigen-presentation machinery, surface co-modulatory signals, or immunosuppressive mediator status of their parent tumor cells. Treatment with glioma-derived exosomes promoted immunosuppressive HLA-DR(low) monocytic phenotypes, but failed to induce monocytic PD-L1 expression or alter the activation of cytotoxic T-cells from patients' peripheral blood by FACS and RT-PCR analyses. Our results suggest that malignant glioma-derived exosomes are restricted in their capacity to directly prime peripheral immunosuppression.

KEYWORDS:

Exosome; Glioma; Immunosuppression; Immunotherapy; Microvesicle

PMID:
26711578
DOI:
10.1016/j.jneuroim.2015.11.025
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center